This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q91208912
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu n'avientu de 2018 scientific article published on 19 December 2018 wetenschappelijk artikel наукова стаття, опублікована в грудні 2018 article scientifique publié en 2018
p:P577
wds:Q91208912-6B18A70D-4477-49F6-AF90-E7BBB8110FDC
wdt:P577
2018-12-19T00:00:00Z
p:P2093
wds:Q91208912-3DC082C8-6FA8-43B7-B46E-F33E42E73187 wds:Q91208912-214489E7-2500-4D72-994C-5328FADDC931 wds:Q91208912-42D9B71A-60E8-492E-88C2-89C4317ACB3D wds:Q91208912-168EA8F8-DDEE-49BB-BF33-1658F820972F wds:Q91208912-0AD6E6D7-37C9-4F54-A300-F7B3578C6AE5 wds:Q91208912-A374C960-FC44-4DA5-B6D9-1EB3E15F32D3 wds:Q91208912-86586CCB-6452-4224-973A-30FEA09D2B57 wds:Q91208912-77362934-58D6-4135-BCD0-B04C564B9990 wds:Q91208912-DB300FE8-5A35-4331-9803-D32448C9D1F5 wds:Q91208912-B96C6173-2FB7-4B2C-A70D-00B78D32C494
wdt:P2093
Sarab Lizard Michèle Beau-Faller Hélène Blons Gérard Zalcman Samia Melaabi Franck Morin Elisabeth Longchampt Jean-Pierre Pignon Fabienne Escande Matthieu Texier
rdfs:label
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2) Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
skos:prefLabel
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2) Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
schema:name
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2) Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
p:P50
wds:Q91208912-0A2E8946-B954-4699-98B0-DCC2BB1880A5 wds:Q91208912-3D03DC70-6D8C-4656-A155-AD403A134475 wds:Q91208912-4A804AE5-C53E-4609-BEEB-506249024548
wdt:P50
wd:Q115583696 wd:Q57419747 wd:Q63845290
p:P1476
wds:Q91208912-45B6A5DB-7BDA-4CD0-A70E-0E106D0C240C
wdt:P1476
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
p:P304
wds:Q91208912-18EC024E-0D50-4C4A-8BB9-782B86A7D83B
wdt:P304
222-230
p:P31
wds:Q91208912-0C320BEA-BF59-4923-A0E5-FEFA5353A34F
wdt:P31
wd:Q13442814
p:P698
wds:Q91208912-F3CF5E97-9C33-451F-AE4F-B3F6FF5EBE81
wdtn:P698
n10:30679079
wdt:P698
30679079
p:P1433
wds:Q91208912-E9A6A210-091B-44A3-BEED-6484270AD609
wdt:P1433
wd:Q332299
p:P433
wds:Q91208912-F9005E56-E481-45A0-A461-53B8DFA748A8
p:P478
wds:Q91208912-D2B50BE5-B3A6-4CC8-A8BB-7B4649CC5EC2
wdt:P433
3
wdt:P478
20
p:P356
wds:Q91208912-7958A023-52A6-406B-9F29-765C21AB4204
wdtn:P356
n12:J.CLLC.2018.12.012
wdt:P356
10.1016/J.CLLC.2018.12.012